Bipolar disorder with binge eating behavior: a genome-wide association study implicates PRR5-ARHGAP8 by McElroy, Susan L. et al.
McElroy et al. Translational Psychiatry  (2018) 8:40 
DOI 10.1038/s41398-017-0085-3 Translational Psychiatry
ART ICLE Open Ac ce s s
Bipolar disorder with binge eating
behavior: a genome-wide association study
implicates PRR5-ARHGAP8
Susan L. McElroy1,2, Stacey J. Winham3, Alfredo B. Cuellar-Barboza4, Colin L. Colby3, Ada Man-Choi Ho 5,
Hugues Sicotte3, Beth R. Larrabee3, Scott Crow6, Mark A. Frye7 and Joanna M. Biernacka 3,7
Abstract
Bipolar disorder (BD) is associated with binge eating behavior (BE), and both conditions are heritable. Previously, using
data from the Genetic Association Information Network (GAIN) study of BD, we performed genome-wide association
(GWA) analyses of BD with BE comorbidity. Here, utilizing data from the Mayo Clinic BD Biobank (969 BD cases, 777
controls), we performed a GWA analysis of a BD subtype defined by BE, and case-only analysis comparing BD subjects
with and without BE. We then performed a meta-analysis of the Mayo and GAIN results. The meta-analysis provided
genome-wide significant evidence of association between single nucleotide polymorphisms (SNPs) in PRR5-ARHGAP8
and BE in BD cases (rs726170 OR = 1.91, P = 3.05E-08). In the meta-analysis comparing cases with BD with comorbid BE
vs. non-BD controls, a genome-wide significant association was observed at SNP rs111940429 in an intergenic region
near PPP1R2P5 (p = 1.21E-08). PRR5-ARHGAP8 is a read-through transcript resulting in a fusion protein of PRR5 and
ARHGAP8. PRR5 encodes a subunit of mTORC2, a serine/threonine kinase that participates in food intake regulation,
while ARHGAP8 encodes a member of the RhoGAP family of proteins that mediate cross-talk between Rho GTPases
and other signaling pathways. Without BE information in controls, it is not possible to determine whether the
observed association reflects a risk factor for BE in general, risk for BE in individuals with BD, or risk of a subtype of BD
with BE. The effect of PRR5-ARHGAP8 on BE risk thus warrants further investigation.
Introduction
Bipolar disorder (BD) and binge eating behavior (BE)
co-occur more often than expected by chance1–3. Esti-
mated to occur in 4.5% of the United States general
population, BE has been reported to occur in over 25% of
individuals with BD1,2. Defined as eating an unusually
large amount of food in a discrete time period with a
sense of loss of control over the eating, BE is a trans-
diagnostic feature of eating disorders: it is a defining
symptom of bulimia nervosa and binge eating disorder,
and may also occur in anorexia nervosa. BD with
comorbid BE is associated with greater psychiatric and
general medical burden than BD without BE, and has been
proposed to be an important clinical BD subtype4. Addi-
tionally, each condition is heritable, with heritability
estimated at 60–85% for BD and 46–74% for BE5–9.
Indeed, parental BD is a risk factor for eating disorders,
including those with BE, in offspring10. Few studies,
however, have evaluated the genetic architecture of the
co-occurrence of BD and BE. Genetic studies of specific
BD sub-phenotypes may help uncover some of the
unknown inheritance of BD. In an earlier study using data
from the Genetic Association Information Network
(GAIN) study of BD, we conducted a genome-wide
association (GWA) analysis of BD subtypes defined by the
presence or absence of a history of BE and a case-only
© The Author(s) 2018
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Joanna M Biernacka (biernacka.joanna@mayo.edu)
1Lindner Center of HOPE, Mason, OH, USA
2Department of Psychiatry and Behavioral Neuroscience, University of
Cincinnati, Cincinnati, OH, USA
Full list of author information is available at the end of the article
Susan L. McElroy and Stacey J. Winham contributed equally to this work.
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
analysis comparing BD subjects with and without BE
history11. In that study, no associations were statistically
significant at the genome-wide level.
In this study we perform similar analyses in an inde-
pendent sample of BD patients from the Mayo Clinic
Biobank, use the new results to evaluate replication of the
prior GAIN results, and conduct a meta-analysis of the
two studies, making this the largest GWA study (GWAS)
of BE in BD to date. To determine if the GWAS results
were enriched for biologically relevant pathways, we then
conduct gene-set and network analysis. We also explore
specific gene regions previously implicated in BE or
related phenotypes.
Methods
Study participants from GAIN
We previously performed GWA analyses of BE using
data from BD cases and controls collected by the Bipolar
Disorder Genome Study Consortium, part of GAIN11,
accessed using dbGaP12. Subjects included 1001 European
American bipolar cases and 1034 mentally healthy Eur-
opean American controls. BD cases met DSM-IV criteria
for bipolar I disorder or schizoaffective disorder deter-
mined by psychiatric interviews based on the Diagnostic
Interview for Genetic Studies (DIGS) 2, 3, or 4, which
included the question, “has there ever been a time in your
life when you went on food binges (i.e., rapid consump-
tion of a large amount of food in a discrete period of time,
usually less than two hours)?”. Based on answering this
question (yes/no), BD cases were classified as having BE
(N= 206) or not having BE (N= 723). BE data was not
available for controls.
Study participants from Mayo Clinic Biobank
Here, a new sample of BD cases from the Mayo Clinic
Bipolar Disorder Biobank13, a collaboration between
Mayo Clinic and the Lindner Center of HOPE, and con-
trols from the Mayo Clinic Biobank14, was used for GWA
analyses of BE. Both biobank protocols were approved by
an institutional review board, and every participant pro-
vided written informed consent to be included in the
biobank and future genetic studies. All subjects from the
Mayo Bipolar Disorder Biobank had a diagnosis of bipolar
I disorder, bipolar II disorder or schizoaffective bipolar
type. Entry criteria included age 18 through 80 years and
no current suicidal ideation or psychosis. The clinical
phenotype of BD subjects was determined with the
Structured Clinical Interview for DSM-IV (SCID)15 and
the Bipolar Biobank Clinical Questionnaire. Current BE
was assessed with the Eating Disorder Diagnostic Scale
(EDDS)16–18. EDDS data was available for 700 of the BD
cases passing genotype QC. For the BD plus BE pheno-
type, subjects had to answer yes on questions 5 and 6 of
the EDDS [“During the past 6 months have there been
times when you felt you have eaten what other people
would regard as an unusually large amount of food (e.g. a
quart of ice cream) given the circumstances?” and “During
the times when you ate an unusually large amount of
food, did you experience a loss of control (feel you
couldn’t stop eating or control what or how much you
were eating)?”], and thus have any BE within the past six
months (N= 192 of 700 BD cases with EDDS data).
The control group was selected from the Mayo Clinic
Biobank14, and excluded potential controls with ICD9
codes for bipolar disorder, schizophrenia, or related
diagnoses in their electronic medical record. BE was not
assessed among the controls.
Genotyping, quality control, and imputation
GAIN samples were genotyped on the Affymetrix
Genome-Wide Human SNP Array 6.0. Quality control
(QC) was performed as described previously11,19. After
QC, the sample included 1001 European American BD
cases and 1034 mentally healthy controls.
Mayo cases and controls (total N= 1864) were geno-
typed using the Illumina HumanOmniExpress platform.
We removed SNPs with call rate < 98%, minor allele
frequency < 0.01, and those demonstrating departures
from Hardy–Weinberg Equilibrium (P< 1e-06). We
excluded subjects with < 98% call rate, one subject from
each related pair (estimated identical-by-descent allele
sharing > .2), and subjects of non-European ancestry. We
used Structure20 to verify European ancestry, and adjusted
for remaining population structure using the first four
principle components. After QC, the Mayo sample con-
sisted of 969 BD cases and 777 healthy controls without
BD.
Genotypes in both the GAIN and Mayo samples were
imputed to the 1000 genomes reference panel, as pre-
viously described for the GAIN sample11. Specifically,
SHAPEIT21 was used for haplotype phasing, followed by
imputation using IMPUTE2.2.222 with the 1000 genome
project reference data (phase 1 data, all populations).
SNPs with dosage R2< 0.3 or MAF< 0.01 were removed
prior to analysis, resulting in more than 8 million SNPs in
both datasets.
Statistical analysis
To identify genetic risk variants of BE in subjects with
BD, we previously performed a GWAS of BE in BD GAIN
subjects (206 BD subjects with BE vs. 723 BD subjects
with no BE)11. We now performed a similar GWAS of BE
using the Mayo sample (192 BD subjects with BE vs. 508
BD subjects with no BE) and then conducted a meta-
analysis of the two studies.
To identify genetic risk variants for a subtype of BD with
BE, we also performed a GWAS of BD with comorbid BE,
comparing BD cases with BE vs. non-bipolar controls in
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both the GAIN11 (206 BD subjects with BE vs. 1034 non-
BD controls) and Mayo (192 BD subjects with BE vs. 777
non-BD controls) samples, and then conducted a meta-
analysis of the results.
In each dataset, logistic regression models were fit for
each SNP using PLINK version 1.0719, adjusted for 4
genomic principle components. SNP values were coded in
terms of allele dosage. Fixed-effects meta-analyses were
performed using R statistical software version 3.2.3, and P
< 5E-8 was considered statistically significant.
Finally, we extracted results for several candidate SNPs/
genes that were previously implicated in BE or related
phenotypes (bulimia nervosa spectrum), including FTO,
NT5C1B, and HTR2A23–25.
Follow-up of GWAS results and gene set and network
analysis
GWAS results were annotated with NCBI Build 37 to
determine location, nearby gene(s), and function. Top
results were examined with the UCSC Genome Browser.
Potential regulatory function was investigated using
ENCODE data via the tools HaploReg (version v4.1)26 and
RegulomeDB (version 1.1)27. Possible expression quanti-
tative trait locus (eQTL) associations between the top
SNPs and brain expression were explored with BRAI-
NEAC data (http://www.braineac.org)28. For genome-
wide significant SNPs, we also explored potential reg-
ulatory mechanisms by visualizing 3D compartment
organization in the region, based on potential chromatin
looping identified with Hi-C analysis, using the bioinfor-
matics tool Juicebox29,30. Because large-scale folding
organization is thought to be very stable across cell
lines30, we visualized the 3D structure using the highest
resolution dataset (data from the GM12878 lympho-
blastoid cell line30). Using the GTEX portal V6p31, we also
examined potential eQTL associations in brain and other
tissues.
Case-only and case-control gene-level and gene-set
analyses were conducted using MAGMA32. Gene-level
tests were performed separately by study with multiple
regression models using principal components of SNP
effects computed from the imputed SNPs with dosage R2
> 0.8 and MAF> 0.01. Gene-level meta-analysis was
performed for 15,420 genes and utilized in the evaluation
of 186 KEGG pathways (http://www.genome.jp/kegg/
kegg1.html). Competitive test p-values were calculated
and corrected for multiple testing via permutation.
Network analysis was performed with Ingenuity Path-
way Analysis (IPA; www.ingenuity.com) using SNP p-
values from the GWAS meta-analyses. SNPs were pre-
filtered using LD-clumping with p ≤ 0.05, resulting in over
70,000 top SNPs considered for network analysis. SNPs
were assigned to the nearest gene using NCBI Build 37,
and the top 2000 genes (ranked by minimum SNP p-
value, all with p< 0.0002) were considered ‘significant’ for
network analysis. De-novo networks of direct and indirect
interactions between significant genes in our data were
constructed based on a functional analysis algorithm that
utilizes published, peer-reviewed literature within the
curated Ingenuity Knowledge Base.
Results
GWAS results
Supplemental Table 1 shows the sample demographics
and supplemental Table 2 and 3 show the top results from
the BE case-only GWAS of the GAIN and Mayo data,
respectively. The Manhattan plot of the corresponding
meta-analysis is shown in Fig. 1, with top results listed in
Table 1. The meta-analysis of BE in BD cases provided
genome-wide significant evidence for association of BE
with a group of SNPs in the PRR5-ARHGAP8 gene, where
the more common allele is associated with reduced risk of
BE behavior among BD patients (top SNPs rs726170 and
rs8139558, OR= 0.52, p= 3.05E-08); the C allele at
rs726170 is less common in BD patients with BE (Mayo
0.84, GAIN 0.81) as compared to those without BE (Mayo
0.89, GAIN 0.90). Suggestive evidence of association with
rs726170 in PRR5-ARHGAP8 was observed in our prior
analysis of this phenotype in the GAIN data (p=
8.0E–08);11 the current analysis of the Mayo data repli-
cated this finding (p= 0.0046), and the meta-analysis
combining the results provided genome-wide significant
evidence for association. Additionally, the meta-analysis
showed suggestive evidence of association of the G allele
at rs7904579 in the CUBN gene with BE behavior among
BD patients (OR= 1.56, p= 1.4E-07), although this
association was not genome-wide significant.
Supplemental Tables 4 and 5 show the top results from
GWAS comparing cases with both BD and BE vs. non-BD
controls in the GAIN and Mayo data, respectively. The
Manhattan plot of the corresponding meta-analysis is
shown in Fig. 2, with top results listed in Table 2.The top
SNP rs111940429, which is genome wide significant (P=
1.2E–08), is in an intergenic region of chromosome
2q12.3, with the closest gene PPP1R2P5; the C allele is less
common in BD patients with BE (Mayo 0.93, GAIN 0.93)
than in controls (Mayo 0.96, GAIN 0.97).
Regulatory analysis results
The genome-wide significant SNP from our case-only
meta-analysis, rs726170, is in high linkage disequilibrium
(LD) with rs9614952 and rs28439052, which are situated
at binding sites for transcription factor STAT3 (Fig. 3). It
is also in complete LD with rs8139558, which is in an
enhancer region of PRR5-ARHGAP8 with H3K4me1 his-
tone mark in adipose cultures26. No significant eQTL
associations between rs726170 and PRR5-ARHGAP8
expression were observed in human brain regions
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studied in BRAINEAC28. Using the GTEX portal (version
V6p)31, rs726170 is a significant eQTL for ARHGAP8 in
tibial nerve (p= 3.8e–9), but has no association with
expression of the next 5′ gene (PHF21B) or the next 3′
gene (PRR5).
Supplemental Fig. 1 shows the 3D genomic organization
around rs726170. Yellow lines indicate block regions
defined by marks of the transcription factor CCCTC-
binding factor (CTCF), which delineates heterochromatin
from euchromatin. This SNP is in the transition region
between two blocks and shows little long range interac-
tions, so it likely affects only the ARHGAP8 gene or
another gene downstream (rather than genes 3′ of ARH-
GAP8), consistent with the GTEX eQTL results.
According to ENCODE data, this region is devoid of
common histone marks in LCL tissues, with the exception
for H3K9me3, normally associated with constitutively
repressed genes.
Furthermore, rs111940429 identified in the case-control
meta-analysis also shows evidence of regulatory function;
specifically, the risk (‘C’) allele in our analysis potentially
disrupts the motif for the transcription factor Fox26.
Gene-set analysis and network analysis results
MAGMA analyses did not identify any gene sets with
statistically significant associations with BE after correc-
tion for multiple testing. The top-ranking gene sets in the
case-only analysis and in the case-control analysis are
shown in Supplemental Table 6 and Supplemental Table
7, respectively.
Constructed IPA networks focus on Neurological Dis-
ease, Psychological Disorders, Cellular Development
(Supplemental Fig. 2), as well as Hereditary Disorders,
Neurological Disease, and Organismal Injury and
Abnormalities (Supplemental Fig. 3). Hub molecules with
at least 5 connections in Network 1 (Supplemental Fig. 2)
include WWOX, CUL3, CAND1, CDC5L, and SMARCA4.
Hub molecules with at least 5 connections in Network 2
(Supplemental Fig. 3) include TADA2A,MED15, TCF7L2,
ATXN1, and RBFOX1.
BE association with candidate genes
We found no evidence of association of BD with
comorbid BE, or BE in BD patients, with a set of SNPs/
genes selected based on prior human candidate gene
studies (FTO, NT5C1B, and HTR2A). No SNP within
these genes was statistically significant after Bonferroni
correction for the number of candidate SNPs tested. The
top result was rs7330461 in HTR2A (uncorrected p=
0.003, corrected p= 0.90).
Discussion
In this study, we utilized two BD case-control GWAS
datasets to explore genetic risk for the sub-phenotype of
Fig. 1 Manhattan plot of GWAS results for the comparison of BD
patients with and without the BE behavior. For each SNP, −log10
(P-value) is plotted against chromosomal position. The labeled SNP is
genome-wide significant at P < 5E–8
Table 1 Meta-analysis of BE in BD cases: top results
SNP Locus Position Gene A1 A2 Mayo
A1
freq
GAIN
A1
freq
Mayo OR Mayo P GAIN OR GAIN P Meta-
analysis
OR
Meta-
analysis
p-value
rs726170 22q13.31 45251811 PRR5-ARHGAP8 C T 0.88 0.88 0.62 0.0046 0.45 8.0E–07 0.52 3.05E–08
rs7904579 10p13 17131753 CUBN G C 0.35 0.37 1.62 6.9E–05 1.50 4.9E–04 1.56 1.36E–07
rs1950038 2q32.1 184444370 intergenic T‘ C 0.30 0.30 1.86 2.1E–06 1.36 0.027 1.60 6.73E–07
rs182107583 2q23.3 150531537 LOC101929321
(lncRNA)
A C 0.96 0.96 0.34 0.0015 0.29 2.0E–04 0.31 1.08E–06
rs76087671 20p11.21 24311177 intergenic C T 0.94 0.95 0.61 0.0497 0.32 1.4E–06 0.43 1.17E–06
Note: Odds ratio (OR) estimates are presented in terms of A1 vs. A2
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BD with comorbid BE. This is the largest GWAS of BE in
BD to date, and no GWAS of BE in the general population
has yet been published.
We demonstrated that BE among BD patients is asso-
ciated with variants of the PRR5-ARHGAP8 gene, a read-
through transcript of neighboring genes PRR5 and ARH-
GAP8. PRR5 is a circadian clock gene that encodes a
subunit of the mammalian target of rapamycin complex 2
(mTORC2) critical for neuronal survival, proliferation,
and differentiation33, as well as energy balance, obesity,
and hyperphagia34. ARHGAP8 encodes a member of the
large RhoGAP family of proteins, which are complex
tissue-specific molecules regulated by lipid binding,
protein–protein interactions, phosphorylation, and other
mechanisms35. RhoGAPs mediate the cross-talk between
Rho GTPases and other signaling pathways, and are
fundamental to multiple cellular processes, such as cel-
lular growth, gene transcription, and apoptosis35. Read-
through transcripts are fusions across adjacent genes
resulting in proteins that share sequence identity with
each individual gene product36. The PRR5-ARHGAP8
read-through occurs in nature37 and is expressed in the
brain31. Despite the unclear function of the PRR5-
ARHGAP8 fusion protein, mTORC2 and Rho GTPases
interact in different cellular processes, for example in
regulating the cytoskeleton38, where this fusion protein
may play a role.
Further information points to a potential regulatory role
of rs726170, although the targets are unclear. This SNP is
Fig. 2 Manhattan plot of GWAS results for the comparison of BD
patients with the BE behavior sub-phenotype to controls. For
each SNP, −log10 (P-value) is plotted against chromosomal position.
The labeled SNP is genome-wide significant at P < 5E–8
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in high LD with SNPs in binding sites for the transcription
factor STAT3 and an enhancer region in adipose tissue.
While we have no evidence of this SNP being an eQTL for
either PRR5 or ARHGAP8 in brain tissue, the variant is an
eQTL for ARGHAP8 in tibial nerve tissue. Additionally,
Hi-C analysis suggested that the 3D chromatin structure
of the region prohibits long-range interactions with genes
that are upstream of the region, suggesting that the target
is either ARHGAP8 or another gene downstream, rather
than PRR5. ARHGAP8 is expressed at low levels in brain
and blood, but high levels in gastrointestinal-related tis-
sues. Given that rs726170 was not strongly associated
with BD with comorbid BE compared to controls, col-
lectively these results suggest that the identified SNP
likely plays a role in BE rather than in BD.
In the meta-analysis of BD cases with BE compared to
controls, we identified a genome-wide significant variant
in an intergenic region of chromosome 2q12.3, with the
nearest gene encoding protein phosphatase 1 regulatory
subunit 2 (PPP1R2), an inhibitor of the serine/threonine
protein phosphatase 1 (PPP1) that binds to the active site
of its catalytic subunit. The PPP1C/PPP1R2 complex has
been shown to participate in neural functioning (calcium-
induced synaptic scaling39, memory suppression40,
and neurodegeneration41,42), as well as mitosis and
meiosis43–46, cell morphology regulation47, and cardiac
function48–50. PPP1R2 is expressed in GABAergic neurons
in the striatum, cortex, and hippocampus51.
Our analyses revealed association trends for other genes
and pathways that were not significant after multiple
testing correction, but may nevertheless reflect important
biological mechanisms. For example, the second top
association signal in the case-only meta-analysis of BE
among BD patients was in the gene encoding cubilin
(CUBN), a receptor for the intrinsic factor-vitamin B12
complex, which is essential for neurodevelopment; its
deficiency has been implicated in various neuropsychiatric
diseases such as depression, schizophrenia, dementia, and
cognitive impairment52,53. In our MAGMA gene-set
analysis comparing BD cases with BE to those without
BE, the canonical Wnt signaling pathway was a top-
ranked pathway; this pathway is critical to neurogenesis,
neurodevelopment54, mood stabilizer mechanism of
action55, and energy balance56. Application of IPA to our
data produced a network that highlighted genes relevant
for neurological and psychological disorders, with the
effector of the canonical Wnt signaling pathway TCF7L2,
a gene involved in genetic risk of BD with comorbid
obesity57,58, as a network hub (Supplemental Fig. 3).
Finally, in our gene-set analysis of BD cases with BE
compared to controls, the cytokine-cytokine receptor
interaction pathway was among the top-ranking path-
ways; this finding is intriguing considering the role of
cytokines in sickness response and the related suppression
of appetite and induction of anhedonia. While possibly
interesting, these results require further evidence from
Fig. 3 Regional association plot of the ARHGAP8-PRR5 gene region, for association with BE in cases with BD
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independent data before their role in binge eating can be
established.
Although no prior GWAS of BE have been performed, a
GWAS of anorexia nervosa identified a variant in SOX2-
OT;59 another variant in this region, rs4854912, was later
confirmed in a GWAS of bipolar patients with either
anorexia nervosa or bulimia nervosa compared to healthy
controls, in an analysis that included GAIN data60. In our
Mayo Biobank sample, we observed no evidence of asso-
ciation of this variant with BE among BD cases, nor in the
comparison with control subjects (all p> 0.50). However,
because our phenotypes here focus on BE rather than
anorexia nervosa or bulimia nervosa diagnoses, these
differences in findings are not surprising. Candidate gene
studies have suggested associations between binge eating
and FTO in adolescents24, binge eating and HTR2A in
young women23, and bulimia nervosa spectrum and
NT5C1B in female twins25, but we did not replicate any of
these findings.
This study has several limitations. Without BE
information in controls, it is not possible to determine
whether the observed association with PRR5-ARHGAP8
reflects risk for BE in general or risk for a subtype of
BD with BE. Additionally, BE was defined differently
in the two data sets. In GAIN subjects, BE was defined
as a lifetime history of food binges, or the rapid con-
sumption of a large amount of food in a discrete period
of time, usually less than two hours. In Mayo subjects,
BE was defined as eating a large amount of food and
having a sense of loss of control in the last six months.
Nonetheless, rates of BE behavior were comparable in
the two samples. Finally, the sample size was limited,
resulting in low power to detect small and even
moderate effects. By reducing phenotypic heterogeneity,
which tends to result in increased power, we obtained
genome-wide significant findings in this relatively small
sample. Nevertheless, it is clear that much larger sample
sizes are needed to identify further genetic risk factors
for BE.
In summary, this study provided genome-wide sig-
nificant evidence for association of BD with comorbid
BE with variants in the PRR5-ARHGAP8 region, and
identified additional regions of interest in the etiology
of BD with comorbid BE. To date, BD genetic risk
factors have been difficult to replicate61, due in part to
extensive disease heterogeneity. The present work
demonstrates the importance of reducing this hetero-
geneity by focusing on sub-phenotypes when investigating
the genetic risk of BD and its comorbidities. Further
population-based studies are needed to untangle whether
the observed genetic association is driven by BD, BE, or
both, and functional studies will be needed to determine
the molecular targets and mechanisms behind the
association.
Data availability
The GAIN dataset (part of Whole Genome Association
Study of Bipolar Disorder) used for the analyses described
in this manuscript were obtained from the database of
Genotypes and Phenotypes (dbGaP) found at http://www.
ncbi.nlm.nih.gov/gap through dbGaP accession number
phs000017.v3.p1. The GTEx data used for the analyses
described in this manuscript were obtained from: http://
www.gtexportal.org/home/bubbleHeatmapPage/
ARHGAP8 and http://www.gtexportal.org/home/gene/
ARHGAP8 on the GTEx Portal accessed on 30 Nov 2016.
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